| Literature DB >> 30393068 |
Craig M Bielski1, Mark T A Donoghue1, Mayur Gadiya2, Aphrothiti J Hanrahan2, Helen H Won3, Matthew T Chang4, Philip Jonsson4, Alexander V Penson4, Alexander Gorelick4, Christopher Harris1, Alison M Schram5, Aijazuddin Syed3, Ahmet Zehir3, Paul B Chapman5, David M Hyman6, David B Solit7, Kevin Shannon8, Sarat Chandarlapaty9, Michael F Berger10, Barry S Taylor11.
Abstract
Driver mutations in oncogenes encode proteins with gain-of-function properties that enhance fitness. Heterozygous mutations are thus viewed as sufficient for tumorigenesis. We describe widespread oncogenic mutant allele imbalance in 13,448 prospectively characterized cancers. Imbalance was selected for through modest dosage increases of gain-of-fitness mutations. Negative selection targeted haplo-essential effectors of the spliceosome. Loss of the normal allele comprised a distinct class of imbalance driven by competitive fitness, which correlated with enhanced response to targeted therapies. In many cancers, an antecedent oncogenic mutation drove evolutionarily dependent allele-specific imbalance. In other instances, oncogenic mutations co-opted independent copy-number changes via the evolutionary process of exaptation. Oncogenic allele imbalance is a pervasive evolutionary innovation that enhances fitness and modulates sensitivity to targeted therapy.Entities:
Keywords: cancer; competitive fitness; exaptation; oncogenes; selection; targeted therapy
Mesh:
Year: 2018 PMID: 30393068 PMCID: PMC6234065 DOI: 10.1016/j.ccell.2018.10.003
Source DB: PubMed Journal: Cancer Cell ISSN: 1535-6108 Impact factor: 31.743